Sinopharm (company)
Search results
Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system.
- News
News - Home_Fosun Pharma
- Leadership
Fosun Pharma is patient-centered and clinical...
- Investors
Fosun Pharma directly operates businesses including...
- Job Applicants
Job Applicants - Home_Fosun Pharma
- Contact
Contact - Home_Fosun Pharma
- R&D
Fosun Pharma connects with global excellent scientific...
- Sustainability
Fosun Pharma improves the research and clinical development...
- About Company_Our Company_Fosun Pharma
Fosun Pharma directly operates businesses including...
- R&D Pipeline_R&D_Fosun Pharma
R&D Pipeline. Guided by innovation and internationalization,...
- News
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (trade name: Fosun Pharma) is a Chinese pharmaceutical company. It is mostly owned by Fosun International. As of 2018, the A shares of the company is a constituent of SSE 180 Index as well as its sub-index SSE MidCap Index.
ABOUT US. Fosun Pharma USA Inc. is a wholly owned subsidiary of Fosun Pharma with a focus on building a fully integrated innovative biopharmaceutical company focused on the US market.
People also ask
Who is Fosun Pharma USA?
Who owns Shanghai Fosun Pharmaceutical?
What makes Fosun Pharma unique?
Who is the CEO of Fosun Pharma?
Fosun for Good, Sharing Happiness. Fosun upholds its original aspirations of developing business for good and “Contribution to Society”, endeavoring to create happier lives for families worldwide. Assisting the fight against Malaria in Africa. Call for long-term public welfare to jointly build a malaria-free world. Rural Doctors Program.
About Us. It's important to care for others and contribute to society. Building a portfolio of high value branded, innovative products for patients with unmet medical needs. PIPELINE. Established over 10 in-house R&D units based on different technologies and modalities. Our diverse pipeline reflects therapeutic areas of interest including:
Performance Highlights: ·During the reporting period, the revenue was RMB 43.952 billion, with a year-on-year growth of12.66%; the net profit after deducting extraordinary gain or loss attributable to owners of the parent was RMB 3.873 billion, with a year-on-year growth of 18.17%;
